- PharmaLogic has opened a new radiopharmaceutical production and research facility in Salt Lake City, Utah, aimed at enhancing patient access to diagnostic and therapeutic products.
- The facility will support the scaling of operations and foster the development of innovative radiopharmaceuticals.
PharmaLogic Holdings Corp., a contract development and manufacturing organisation (CDMO) and radiopharmacy solutions provider, has announced the official opening of its new radiopharmaceutical production and research facility in Salt Lake City, Utah. The facility is designed to support the delivery of diagnostic and therapeutic radiopharmaceuticals across North America.
The opening marks a key milestone for PharmaLogic’s mission to improve patient access to radiopharmaceuticals, particularly in the Canyons region where many of these products are currently unavailable. The facility will not only scale existing production but will also focus on research and development of new radiopharmaceuticals.
Steve Chilinski, CEO of PharmaLogic, stated: “PharmaLogic is pleased to announce the opening of our new cyclotron facility, a significant milestone in our mission to provide innovative healthcare solutions.” He added that the company is committed to enhancing access to these diagnostics through partnerships with healthcare providers and industry stakeholders.
The new facility represents years of planning and construction. Scott Holbrook, Chief Strategy Officer and General Manager of PharmaLogic, said, “This milestone marks the beginning of a new era for PharmaLogic, one that will expand access to life-saving diagnostics for the local community while also serving as a hub for innovative research and development.”
Read about Radiopharmaceutical CDMO Market here.
Stay ahead of trends and best practices
